Immuneering Corporation

US$3.68As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:IMRXHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (25.67%)
Div yield —
ROE (33.53%)
Biotechnology
Beta (5Y) 0.46
PE TTM —
TSR TTM (46.43%)
Mkt cap US$238.3M
ROIC (22.85%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.80
3.15%
297.72%
Hold 5|2|10|4|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.08
0.09
0.09
0.10
23.81%
27.50%
15.61%
28.57%
Revenue$M
16.51
16.70
16.63
16.79
(1.10%)
0.07%
(1.74%)
(1.12%)
Peers (US$238.3M)
Cap (US$)
PE
241.3M
—
Capital
TTM
5Y
10Y
Leveragex
0.794
0.127
0.130
EBIT/Intx
1.390
0.339
0.352
Own earn%
(53.86)
(32.00)
(16.18)
Sh yield%
20.36
12.88
13.02
Owners
Insiders/Inst%
14.69
62.40
Short interest%
3.20
SBC / revenue%
0.29
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
15–23
$1 testx
—
Incr. ROIC%
3